MDT

95.71

+0.2%↑

VEEV

286.05

-0.32%↓

A

136.79

+0.17%↑

HQY

90.64

+0.08%↑

PHR.US

21.96

-1.61%↓

MDT

95.71

+0.2%↑

VEEV

286.05

-0.32%↓

A

136.79

+0.17%↑

HQY

90.64

+0.08%↑

PHR.US

21.96

-1.61%↓

MDT

95.71

+0.2%↑

VEEV

286.05

-0.32%↓

A

136.79

+0.17%↑

HQY

90.64

+0.08%↑

PHR.US

21.96

-1.61%↓

MDT

95.71

+0.2%↑

VEEV

286.05

-0.32%↓

A

136.79

+0.17%↑

HQY

90.64

+0.08%↑

PHR.US

21.96

-1.61%↓

MDT

95.71

+0.2%↑

VEEV

286.05

-0.32%↓

A

136.79

+0.17%↑

HQY

90.64

+0.08%↑

PHR.US

21.96

-1.61%↓

Search

Arrowhead Pharmaceuticals Inc

Gesloten

SectorGezondheidszorg

35.81 1.42

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

35.22

Max

35.62

Belangrijke statistieken

By Trading Economics

Inkomsten

-547M

-179M

Verkoop

-515M

28M

Winstmarge

-643.397

Werknemers

609

EBITDA

-563M

-166M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+0.96% upside

Dividenden

By Dow Jones

Volgende Winsten

25 nov 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

2.9B

5.2B

Vorige openingsprijs

34.39

Vorige sluitingsprijs

35.81

Nieuwssentiment

By Acuity

72%

28%

344 / 371 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bearish Evidence

Arrowhead Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

12 okt 2025, 21:50 UTC

Acquisities, Fusies, Overnames

Caterpillar to Acquire Australia's RPM Global for $730 Million

10 okt 2025, 21:38 UTC

Acquisities, Fusies, Overnames

Strathcona Resources Terminates Take-Over Bid for MEG Energy

12 okt 2025, 23:47 UTC

Marktinformatie

Gold Rises, Buoyed by Monetary Debasement Fears -- Market Talk

12 okt 2025, 23:39 UTC

Marktinformatie

Oil Rises on Likely Technical Recovery, Mildly Positive Sentiment -- Market Talk

12 okt 2025, 23:22 UTC

Marktinformatie

New Zealand Braces For Renewed Trade War Uncertainty -- Market Talk

12 okt 2025, 23:16 UTC

Acquisities, Fusies, Overnames

Caterpillar Inc. Enters Into Agreement To Acquire RPMGlobal >CAT RUL.AU

12 okt 2025, 22:32 UTC

Marktinformatie

Copper, U.S. Thermal Coal Stand Out as Metals Ride Macro Tailwinds -- Market Talk

12 okt 2025, 21:28 UTC

Acquisities, Fusies, Overnames

RPM Global Says Board Unanimously Recommends Shareholders Accept Caterpillar Offer

12 okt 2025, 21:28 UTC

Acquisities, Fusies, Overnames

RPM Global Agrees to Takeover by Caterpillar

12 okt 2025, 21:28 UTC

Acquisities, Fusies, Overnames

RPM Global Says Caterpillar Offering A$5.00/Share in Cash

11 okt 2025, 08:20 UTC

Marktinformatie

Financial Services Roundup: Market Talk

11 okt 2025, 00:18 UTC

Acquisities, Fusies, Overnames

Why Biotech May Be Back -- Barrons.com

10 okt 2025, 21:07 UTC

Winsten
Acquisities, Fusies, Overnames

Dell Is Just Beginning to Tell Its AI Story. Buy the Stock. -- Barrons.com

10 okt 2025, 20:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

10 okt 2025, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

10 okt 2025, 20:50 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Health Care Roundup: Market Talk

10 okt 2025, 20:06 UTC

Marktinformatie

Fed Won't Publish Monthly Industrial Data Next Week -- Market Talk

10 okt 2025, 20:06 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

10 okt 2025, 19:56 UTC

Marktinformatie

U.S.-China Tension Weighs Down on Treasury Yields, Dollar -- Market Talk

10 okt 2025, 19:20 UTC

Marktinformatie

Oil Futures Sink As Trump Rekindles Trade Tensions -- Market Talk

10 okt 2025, 19:02 UTC

Marktinformatie

U.S. Natural Gas Futures Post Weekly Loss -- Market Talk

10 okt 2025, 18:58 UTC

Marktinformatie

Canada's Jobs Gain Marks a 'Head Fake' For Economy -- Market Talk

10 okt 2025, 18:52 UTC

Marktinformatie

PepsiCo Lays Groundwork for Improvement -- Market Talk

10 okt 2025, 18:47 UTC

Marktinformatie

Precious Metals Turn Higher After Profit-Taking Slide -- Market Talk

10 okt 2025, 18:35 UTC

Marktinformatie

Canada's Next Rate Cut May be Pushed to December -- Market Talk

10 okt 2025, 18:31 UTC

Marktinformatie

Canada's Labor Market Firming. But Conditions Vary Across Country -- Market Talk

10 okt 2025, 17:32 UTC

Marktinformatie

U.S. Oil Rig Count Declines by Four to 418 -- Market Talk

10 okt 2025, 16:55 UTC

Winsten

These Stocks Are Moving the Most Today: MP Materials, Nvidia, Alibaba, Venture Global, Applied Digital, Qualcomm, and More -- Barrons.com

10 okt 2025, 16:20 UTC

Marktinformatie

Financial Services Roundup: Market Talk

10 okt 2025, 16:20 UTC

Marktinformatie

Auto & Transport Roundup: Market Talk

Peer Vergelijking

Prijswijziging

Arrowhead Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

0.96% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 35.75 USD  0.96%

Hoogste 80 USD

Laagste 12 USD

Gebaseerd op 11 Wall Street-analisten die 12-maands prijsdoelen bieden voor Arrowhead Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

11 ratings

6

Buy

5

Hold

0

Sell

Technische score

By Trading Central

11.5 / 12.23Steun & Weerstand

Korte Termijn

Weak Bearish Evidence

Gemiddeld Termijn

Weak Bearish Evidence

Lange Termijn

Weak Bearish Evidence

Sentiment

By Acuity

344 / 371 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Arrowhead Pharmaceuticals Inc

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.
help-icon Live chat